The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KTOV | -79.46% | -99.1% | -60.97% | -100% |
| S&P | +12.83% | +86.37% | +13.24% | +227% |
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.
No news articles found for Purple Biotech.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$58.27K | -18.9% |
| Market Cap | $5.19M | -43.5% |
| Market Cap / Employee | $576.14K | 0.0% |
| Employees | 9 | -55.0% |
| Net Income | -$1,311.10K | -96.3% |
| EBITDA | -$1,315.12K | 36.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.59M | 76.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $49.00K | 28.9% |
| Short Term Debt | $207.00K | 12.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.85% | 20.3% |
| Return On Invested Capital | -37.73% | 6.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,537.29K | 60.6% |
| Operating Free Cash Flow | -$1,008.79K | 68.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.28 | 0.21 | 0.19 | 0.05 | -80.57% |
| Price to Tangible Book Value | 5.20 | 1.37 | 1.29 | 0.39 | -92.48% |
| Enterprise Value to EBITDA | -3.90 | -0.11 | -0.53 | 5.73 | -428.75% |
| Return on Equity | -21.6% | -12.4% | -8.6% | -10.6% | -69.34% |
| Total Debt | $183.00K | $137.00K | $103.00K | $256.00K | 15.32% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
